Adoption and cost-effectiveness of IPF therapies
Fibrotic remodelling occurs in many diseases. Thinking about idiopathic pulmonary fibrosis (IPF) as a ‘purely’ fibrotic condition, with currently unknown aetiology, may offer strategic insights into IPF drug development that are similarly applicable to other indications. In this blog we look at the adoption and cost-effectiveness of two approved IPF therapies, nintedanib and pirfenidone, and […]
Happy Birthday TherapeutAix! Celebrating our third year
As TherapeutAix celebrates our three-year birthday this month, we thought it would be a great opportunity to take a look back at our achievements over the last year and share some of our top highlights, including events we’ve hosted and attended, projects we’ve worked on, and our latest publications. Welcoming new partners Following a fruitful […]
Reflections from ERS
Having joined a wide range of sessions at the virtual ERS meeting last week, we were keen to share some of our reflections. Despite the virtual format there was still a huge amount of information, so we have decided to limit this to just 4 take-home messages that we came away with. What’s next in COPD? When working with […]
Working in Respiratory Diseases – Our Capabilities
As this year’s ERS meeting is about to kick off, we’ve looked back at the last three years at TherapeutAix and the 20 projects we have supported in the respiratory space. Most of these projects have been in pulmonary fibrosis, but there were also projects targeting COPD and other pulmonary indications. Our work in the […]
Collaboration and Outsourcing in Drug Discovery – Presentation
Last month, we had the pleasure of hosting the “Collaboration and Outsourcing in Drug Discovery” Workshop at this year’s Bio2Business BOS Virtual event. The workshop provided an excellent opportunity to explain the TherapeutAix Approach, using science-led collaboration with our network of R&D partners to offer bespoke solutions to challenges. Included in the workshop were talks […]
NASH – Challenges for drug development
It’s International NASH Day – and it’s also a while since we have last discussed NASH on the blog. In fact, even more has changed from the time when our review on NASH was published in 2019 – all 4 Phase III programs that were ongoing at that time (for obeticholic acid, elafibranor, cenicriviroc, and […]
Pitfalls with Oral Drug Administration in IPF
In the first 3 parts of our blog series on targeted delivery in idiopathic pulmonary fibrosis (IPF), we focused on the potential of inhaled delivery and other targeting strategies to deliver efficacy uplifts for agents as an add-on to the standard of care, while minimising the likelihood of additive side effects. In this fourth installment, we highlight […]
Thoughts from the Extracellular Matrix Pharmacology Symposium
Last week the TherapeutAix team participated in the excellent Extracellular Matrix Pharmacology Symposium, hosted by our network partner Nordic Bioscience. This was a 2-day virtual event, with more than 500 scientists attending to share research and discuss all things extracellular matrix (ECM). Here on the blog, we are revisiting 3 points that got us thinking. Correlations with disease: Throughout the meeting, there was data demonstrating that differences in matrix […]
It’s Rare Disease Day
Worldwide, 473 million people suffer from a rare disease1. But every single one of these diseases is not frequent at all – with some just occurring in a handful of patients. Regulatory pathways and incentives for drug development in rare diseases have facilitated the development of drugs for these indications, both by large pharma companies as well as by many biotechs. In today’s blog […]
Targeting Drug Effects in IPF
In the first two parts of our blog series on drug delivery in idiopathic pulmonary fibrosis (IPF), we focused on inhalation. In this third instalment, we showcase alternative approaches to focusing drug effects to the lung. As we mentioned previously, in the future treatment of IPF, new approaches will need to be compatible, at least initially, with the drugs used currently as “standards of care” (SoC). […]